Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people!

Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.

In the past nearly 4 years, Durst DST has provided full FDA certification consulting services, from quality system construction to production site audit improvement, and FDA formal audit to provide full guidance services. Finally, with the cooperation of both parties, DST has passed PAI formal inspection twice in a row. Eventually, the customer's injection products will be delivered to the United States. Currently, Durst DST is helping customers with the third phase of FDA projects, and more varieties and products will enter the US market. Cai Zong, vice president of Huiyu, is also optimistic about the follow-up business that will continue to go out to sea, and will continue to strengthen the development of the EU and US markets, expressing that he will continue to complete the GMP certification work in the United States for the remaining other workshops.

In recent years, after years of national procurement, health insurance negotiations after the baptism, the market competition pattern is generally clear, volume for price is requiring all pharmaceutical companies to be more pragmatic. In this context, the "internal volume" of the domestic generic drug market is intensifying, and the speed of "going out" is accelerating. Under the increasingly severe industry situation, pharmaceutical companies will inevitably need to go out and go international in the future. In the future, all pharmaceutical companies that want to go overseas will inevitably need to face the review of drug regulatory agencies in various countries, but we do not need to be afraid, because our pharmaceutical production The management level has been developing at a high speed. As long as pharmaceutical companies are fully prepared, international certification inspections are not an insurmountable mountain. Durst DST can provide professional European and American GMP consulting services for pharmaceutical companies to help more pharmaceutical companies "go out". It is also the concept of Durst DST, which continues to promote the advancement of domestic enterprises john young!

DST DST served Sichuan Huiyu, Chengdu Shengnuo, Taiwan lotus, China Resources Sanjiu, Sinopharm Group, Lizhu Pharmaceutical, Kangtai Biology, Nanjing Sansheng Pharmaceutical, Yangzijiang Pharmaceutical, Guangzhou Baiyunshan Pharmaceutical and other well-known pharmaceutical enterprises to help customers successfully pass FDA and EU GMP official inspection through comprehensive audit, system improvement, simulation audit and orientation training and other consulting services, and obtained high evaluation from inspectors, let more and more pharmaceutical companies customers will be products to sea!